Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kura Oncology (DE:KUR)
FRANKFURT:KUR
Kura Oncology (KUR) Stock Price & Analysis
0 Followers
KUR Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€7.05 - €21.40
Previous Close€19.05
Volume0.00
Average Volume (3M)50.00
Market Cap
€1.46B
Enterprise Value€1.08B
Total Cash (Recent Filing)$423.96M
Total Debt (Recent Filing)$17.20M
Price to Earnings (P/E)N/A
Beta0.12
Next Earnings
Aug 01, 2024EPS Estimate
-€0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding76,180,620
10 Day Avg. Volume0
30 Day Avg. Volume50
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)3.95
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-11.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-9.61
Forecast
1Y Price Target
€28.74Price Target Upside50.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Kura Oncology News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressFirst ccRCC patient dosed in KO-2806 combination studies indicates progression in clinical trials.
Drug Development MilestonesKura has outlined clear upcoming milestones for its clinical programs, with several key developments expected by mid-2024.
Financial StrengthThe company has a substantial cash runway expected into 2027, indicating a strong financial position.
Bears Say
Drug EfficacyQuestions on the drug's overall activity have emerged due to lack of activity in the KMT2A-r population.
EarningsKura reported no revenue for the fourth quarter.
Stock ValuationThe stock could decline significantly if efficacy and safety concerns arise.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
7.93% Other Institutional Investors
92.07% Public Companies and
Individual Investors
KUR FAQ
What was Kura Oncology’s price range in the past 12 months?
Kura Oncology lowest stock price was €7.05 and its highest was €21.40 in the past 12 months.
What is Kura Oncology’s market cap?
Currently, no data Available
When is Kura Oncology’s upcoming earnings report date?
Kura Oncology’s upcoming earnings report date is Aug 01, 2024 which is in 78 days.
How were Kura Oncology’s earnings last quarter?
Kura Oncology released its earnings results on May 02, 2024. The company reported -€0.547 earnings per share for the quarter, missing the consensus estimate of -€0.507 by -€0.04.
Is Kura Oncology overvalued?
According to Wall Street analysts Kura Oncology’s price is currently Undervalued.
Does Kura Oncology pay dividends?
Kura Oncology does not currently pay dividends.
What is Kura Oncology’s EPS estimate?
Kura Oncology’s EPS estimate is -€0.58.
How many shares outstanding does Kura Oncology have?
Currently, no data Available
What happened to Kura Oncology’s price movement after its last earnings report?
Kura Oncology reported an EPS of -€0.547 in its last earnings report, missing expectations of -€0.507. Following the earnings report the stock price went down -5.147%.
Which hedge fund is a major shareholder of Kura Oncology?
Among the largest hedge funds holding Kura Oncology’s share is Deerfield Management Company, LP. It holds Kura Oncology’s shares valued at 76M.
---
Kura Oncology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€28.74 (50.85% Upside)
€28.74 (50.85% Upside)
Blogger Sentiment
Bullish
DE:KUR Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
68.38%
12-Months-Change
Fundamentals
Return on Equity
-37.34%
Trailing 12-Months
Asset Growth
30.03%
Trailing 12-Months
Company Description
Kura Oncology
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.
---
KUR Company Deck
---
KUR Earnings Call
Q1 2024
0:00 / 0:00
---
KUR Stock 12 Month Forecast
Average Price Target
€28.74
▲(50.85% Upside)
Technical Analysis
Best Analysts Covering KUR
1 Year
1 Year Success Rate
11/16 ratings generated profit
1 Year Average Return
+52.85%
reiterated a buy rating yesterday
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 68.75% of your transactions generating a profit, with an average return of +52.85% per trade.
---